SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 49.96-6.4%Jan 30 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Biomaven who wrote (16451)4/14/2005 9:08:20 AM
From: Biomaven  Read Replies (2) of 52153
 
Turns out that Aloxi coming in light on revenues can apparently be attributed to the entire chemo market slowing down in January because of concerns over the new reimbursement procedures. Also some impact from big Kytril sales to wholesalers in December - also a one-time event. February apparently was much better, and so analysts (thanks, W) seem to be viewing this as no more than a temporary hiccup. Aloxi continued to gain share.

Peter
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News